Calcium Dobesilate Protects Against D-Galactose-Induced Hepatic and Renal Dysfunction, Oxidative Stress, and Pathological Damage Publisher Pubmed



Hakimizadeh E¹ ; Zamanian MY^{2, 3} ; Damankhorshid M¹ ; Gimenezllort L⁴ ; Sciorati C⁵ ; Nikbakhtzadeh M⁶ ; Moradbeygi K^{6, 7} ; Kujawska M⁸ ; Kaeidi A^{1, 9} ; Taghipour Z¹⁰ ; Fatemi I¹¹
Source: Fundamental and Clinical Pharmacology Published:2022

Abstract

Calcium dobesilate (CaD) is used for the treatment of diabetic retinopathy and nephropathy. This agent exerts antioxidant effects. In the present study, we evaluated the protective effects of oral administration of CaD against hepatorenal damages in a mice model of aging induced by d-galactose (d-gal). We used 28 male albino mice, which equally and randomly were divided into four groups as follows: intact, aging (d-gal at the dose of 500 mg/kg, p.o.), aging + CaD 50 (d-gal plus CaD at the dose of 50 mg/kg), and aging + CaD 100 (d-gal plus CaD at the dose of 100 mg/kg, p.o.). All drugs were administered orally once a day for 42 days. The liver and kidney damages were evaluated by measuring mass indices, levels of serum creatinine and blood urea nitrogen, and activities of serum alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase and by histopathological evaluation. Moreover, hepatic and renal tissue oxidant/antioxidant markers (malondialdehyde, superoxide dismutase, catalase, and glutathione peroxidase) were measured. The results showed that d-gal treatment induced significant oxidative stress in the kidney and liver that was paralleled by dysfunctions and histological alterations of these organs. CaD significantly improved the liver and kidney indices, implemented functional capacity of the liver and kidney, as well as decreased oxidative stress enhancing antioxidative enzyme activities. CaD treatment also inhibited the development of histological alterations of both kidney and liver. CaD might represent a promising therapeutic agent for the attenuation of hepatorenal injuries induced by aging. © 2022 Societe Francaise de Pharmacologie et de Therapeutique.